<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This was a retrospective, comparative study focused on the extended follow-up of 192 transfusion-dependent patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> treated (n </plain></SENT>
<SENT sid="1" pm="."><plain>83) or not treated (n </plain></SENT>
<SENT sid="2" pm="."><plain>109) with recombinant erythropoietin alpha (r-EPO) as single agent during the course of their disease </plain></SENT>
<SENT sid="3" pm="."><plain>The results supported the safety of this treatment in the long term and also showed a significant survival advantage (median 52 months vs. 31 months, p&lt;0.0095) in responding patients as compared to non-responding ones or to subjects never treated with r-EPO </plain></SENT>
<SENT sid="4" pm="."><plain>At multivariate analysis, response to r-EPO maintained an independent prognostic value on OS </plain></SENT>
</text></document>